Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
EXPARELZILRETTAPositive
AI Analysis
Summary
Viatris has agreed to acquire Pacira BioSciences, adding two marketed non-opioid pain management drugs (EXPAREL and ZILRETTA) to strengthen its innovative medicines portfolio and expand its presence in pain therapies.
Importance:8/10
Sentiment:
0.70
M&Anon-opioid paininnovative medicinespatent-protectedmarketed drugs
Related Companies
Read the original article
Published by PR Newswire Biotech on October 8, 2026 11:45 AM